DexCom (DXCM)
(Delayed Data from NSDQ)
$124.34 USD
-13.67 (-9.91%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $124.45 +0.11 (0.09%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
DXCM 124.34 -13.67(-9.91%)
Will DXCM be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for DXCM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DXCM
DexCom (DXCM) Q1 Earnings Beat, Strong CGM Demand Continues
DexCom (DXCM) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
DXCM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Bulls Look Optimistic About DexCom (DXCM): Should You Buy?
DexCom (DXCM) to Report Q1 Earnings: What's in the Cards?
Ahead of DexCom (DXCM) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Other News for DXCM
DexCom (DXCM)'s Market Valuation: A Comprehensive Analysis
ABT, DHR, DXCM: Which “Strong Buy” Healthcare Stock Has More Upside?
What You Missed On Wall Street This Morning
DexCom price target raised by $9 at Raymond James, here's why
Analysts Are Bullish on Top Healthcare Stocks: Regeneron (REGN), Gilead Sciences (GILD)